...

A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Patients With Solid Malignancies

This is a first-in-human study to learn about the study drug GS-9716.

Why this Research Matters

This study will learn more about the study drug GS-9716 given alone or in combination with other anti-cancer agents in patients with advanced solid tumors.

Who can Participate

Adult

Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. Visit ClinicalTrials.gov to learn more about this study.

Study ID

Protocol Number: 23-2253
More information available at ClinicalTrials.gov: NCT05006794

Meet the Team

Image of Principal Investigator

Jennifer Diamond, MD

Principal Investigator

Categories

Locations